A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a rather aggressive disease and the natural course of this lymphoma is very dismal. However, first the introduction of anthracycline-containing chemotherapy regimens and then the addition of rituximab were important steps forward. Since no complete real-life analyses have yet been published, we analyzed all patients… (More)

Topics

  • Presentations referencing similar topics